Hairy Cell Leukemia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Conditions: Follicular Lymphoma; Mantle Cell Lymphoma; Hairy Cell Leukemia; Lymphoplasmacytic Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia Interventions: Drug: CD22CART Infusion Sponsors: Stanford University; The Leukemia and Lymphoma Society Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Conditions: Recurrent Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia Variant Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Venetoclax Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients
Condition: Hairy Cell Leukemia Intervention: Sponsor: Power Life Sciences Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 16, 2023 Category: Research Source Type: clinical trials
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Condition: Hairy Cell Leukemia Intervention: Drug: Low dose vemurafenib plus rituximab Sponsor: Scripps Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2022 Category: Research Source Type: clinical trials
